Allergy · 2023 · 37 citations · 39 references
Life SciencesImmunologyPharmacotherapyClinical ImmunologyImmunotherapyInflammationAtopic DermatitisChronic RhinosinusitisEosinophilic DisordersNasal PolyposisNasal PolypsChronic Rhinosinusitis ExaminationCytokine Receptor ExpressionDupilumab ResponseEosinophil RecruitmentEosinophil-mediated InflammationEosinophilic Disease TherapyFlow Cytometry ImmunophenotypingPeripheral Eosinophilia
BACKGROUND: Dupilumab, a monoclonal anti-IL-4Rα antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS). Clinical studies had reported a transient increase in blood eosinophils during dupilumab therapy. This study aimed to assess the impact of elevated blood eosinophils on clinical outcome and to investigate the cause of high blood eosinophil levels under dupilumab therapy. METHODS: Patients suffering from diffuse type 2 CRS treated with dupilumab were examined on days 0, 28, 90, and 180 after therapy start. Sino-Nasal-Outcome-Test Score (SNOT-22), Total Nasal Polyp Score (TNPS), and blood samples were collected. Cytokine measurements and proteomics analysis were conducted. Flow cytometry analysis measured receptor expression on eosinophils. RESULTS: Sixty-eighty patients were included. Baseline eosinophilia ≥0.3G/L was observed in 63.2% of patients, and in 30.9% of patients, eosinophils increased by ≥0.5G/L under dupilumab. Subjects with eosinophilia ≥0.3G/L at baseline had the best SNOT-22 mean change compared to no eosinophilia. Eosinophil elevation during dupilumab therapy had no impact on clinical scores. The eosinophil adhesion molecule VCAM-1 decreased significantly during therapy in all patients. The chemokine receptor CXCR4 was significantly down- and IL-4 upregulated in subjects with eosinophil increase. CONCLUSION: Our findings suggest that increased eosinophils in type 2 CRS are associated with a good clinical response to dupilumab. Patients with elevated IL-4 at baseline developed dupilumab-induced transient eosinophilia. We identified the downregulation of VCAM-1 and surface markers CD49d and CXCR4 on eosinophils as possible explanations of dupilumab-induced eosinophilia.
39
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
W.J. Fokkens, Valerie J. Lund, C. Hopkins et al. · Rhinology Journal · 2020 · 5.5K citations · Full text
Medicine, Otolaryngology, Surgery +16
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Medicine, Dermatology, Immunology +12
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian Pavord et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text
Pharmacy, Immunology, Pharmacology +13